Magee Thomson Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Magee Thomson Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Sell	10 -5	-33%	-$372	﹤0.01%	70
2016 Q4	$1K	Sell	15 -7	-32%	-$508	﹤0.01%	73
2016 Q3	$2K	Sell	22 -4	-15%	-$222	﹤0.01%	30
2016 Q2	$1K	Sell	26 -58	-69%	-$2.42K	﹤0.01%	66
2016 Q1	$4K	Hold	84	–	–	﹤0.01%	73
2015 Q4	$8K	Buy	84 +11	+15%	+$869	﹤0.01%	34
2015 Q3	$5K	Buy	73 +17	+30%	+$1.41K	﹤0.01%	57
2015 Q2	$5K	Sell	56 -109	-66%	-$7.1K	﹤0.01%	73
2015 Q1	$8K	Buy	+165	New	+$4.68K	﹤0.01%	40

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Magee Thomson Investment Partners's EGRX Position: Q1 2017 in Review

Magee Thomson Investment Partners reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 33% in Q1 2017, selling an estimated $372 and leaving 10 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #70.

Magee Thomson Investment Partners first reported a position in EGRX in Q1 2015 and has held it in 9 quarters since. The position peaked at $8K in Q4 2015. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

Magee Thomson Investment Partners held 10 shares of Eagle Pharmaceuticals, Inc. worth $1K as of Q1 2017.
Magee Thomson Investment Partners sold 5 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $372.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #70 holding.
Magee Thomson Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and has held it in 9 quarters since.
Magee Thomson Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $8K in Q4 2015.
147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.